BERWYN, Pa.– Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that Gerald W. Bruce has been appointed as President and CEO of Novvae™ Pharmaceuticals, Virpax’s wholly-owned subsidiary focused solely on advancing the Company’s OTC pipeline.
Mr. Bruce has spent over 30 years in the pharmaceutical and medical nutrition industries. Most recently, he served as a Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division. Prior to this position, he has held roles of increasing responsibility at Nitromed, Inc. and Bristol-Meyers Squibb. Mr. Bruce began his career at Johnson and Johnson and spent 13 years there starting as a sales representative and moving up the ranks to become a Group Marketing Director in Analgesics. He has a BA from Lincoln University and an Executive Master’s Degree in Leadership from Georgetown University’s McDonough School of Business.
“Gerald, with his background in the pharma and medical nutrition industries, is uniquely positioned to lead Novvae. His experience and knowledge of the OTC market will be beneficial to us as we advance AnQlar™ as well as add new nonprescription product candidates that will utilize our novel delivery technologies,” commented Anthony P. Mack, Chairman and CEO of Virpax.
